CPCCOEt

CPCCOEt is a selective, non-competitive antagonist and negative allosteric modulator (NAM) of the metabotropic glutamate receptor 1 (mGluR1). It is primarily utilized as a pharmacological research tool to investigate the role of mGluR1 in neuronal signaling and, more recently, in immunomodulation. Research presented at AACR 2026 identifies mGluR1 as a critical glutamatergic checkpoint in CD8+ T cells; CPCCOEt-mediated inhibition of this receptor disrupts TCR-driven signaling, calcium flux, and metabolic activity, ultimately impairing T cell proliferation and cytotoxic effector function. In preclinical models, the use of CPCCOEt has been shown to increase the burden of metastatic pulmonary nodules, highlighting the importance of mGluR1 signaling in sustaining anti-tumor immunity.

Other names

7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester7-hydroxyimino-cyclopropan[b]chromen-1a-carboxylic acid ethyl ester